← Leaderboards
Sydney Fobare
Ohio State University
$195,812
Attributed
$195,812
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5K · FY2021–25$100K$75K$50K$25K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$195,812 · 1
By mechanism
F30$195,812 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Ramiro Garzon$6,835,986
- John F Sheridan$19,868,269
- Dehua Pei$17,575,721
- Yang Liu$21,443,530
- Michael A Caligiuri$65,062,344
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyExperimental DesignsAcute Myelocytic LeukemiaDoctor Of PhilosophyAdverse OutcomeApoptoticAnimalsBiologyCell LineAcute Myeloid Leukemia CellChemoresistanceChemotherapyClinical SkillsClonal ExpansionCommunicationComprehensive Cancer CenterCritical ThinkingCytokineCytotoxic ChemotherapyData SetDisease-Free SurvivalCellsDoctoral StudentFda Approved
Grant awards (5)
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance$54,538
F30 · FY2025 · CA · contact PI
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance$53,974
F30 · FY2024 · CA · contact PI
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance$35,447
F30 · FY2023 · CA · contact PI
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance$9,032
F30 · FY2023 · CA · contact PI
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistance$42,821
F30 · FY2021 · CA · contact PI